Nutriband Inc. Warrant

Nutriband Inc. announced key milestones from its January 2026 Annual Shareholders Meeting, including the addition of two new directors with strong financial and operational backgrounds. The company reported progress on its AVERSA™ abuse-deterrent fentanyl patch development, including patent grants, manufacturing scale-up completion, and FDA Typ...

Nutriband Inc. reported significant progress in 2025 including the sale of 90% of its Pocono subsidiary to EarthVision Bio for $5M with no shareholder dilution, a 25% preferred stock dividend, and major advances in its lead product AVERSA Fentanyl abuse-deterrent patch. The company received FDA Type C Meeting approval, completed manufacturing sca...

Nutriband Inc. announced the sale of a 90% stake in its subsidiary Pocono Pharmaceutical to EarthVision Bio for $5 million USD, with Nutriband shareholders retaining 10% ownership. The company plans to use proceeds to develop AVERSA Fentanyl, an abuse-deterrent opioid patch with potential annual US sales of $80-200 million. EarthVision Bio is dev...

Nutriband met with the FDA to discuss its AVERSA™ FENTANYL abuse deterrent patch, receiving guidance on regulatory pathway, manufacturing, and clinical study plans for a potential first-of-its-kind worldwide abuse deterrent fentanyl patch.

Nutriband has partnered with Brand Institute to develop a commercial brand name for its lead product, an abuse deterrent fentanyl transdermal patch utilizing AVERSA™ technology, aimed at preventing drug misuse and accidental exposure.